Sirius Collaborates with Vanderbilt on PGx Test | GenomeWeb

NEW YORK (GenomeWeb News) – Diagnostics developer Sirius Genomics will collaborate with Vanderbilt University to study patients in a biomarker study for a drug aimed at treating severe sepsis, the company said today.

The pharmacogenomics company will work with Vanderbilt's Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study to continue development of a diagnostic to assess responsiveness to recombinant human activated Protein C. The drug is sold by Eli Lilly under the trade name Xigris.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.